Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Sean Laaman Analyst Performance

Analyst at Morgan Stanley

Sean Laaman is a stock analyst at Morgan Stanley focused in the medical sector, covering 14 publicly traded companies. Over the past year, Sean Laaman has issued 37 stock ratings, including buy, hold, and sell recommendations. While full access to Sean Laaman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sean Laaman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
40 Last 5 Years
Buy Recommendations
69.44% 25 Buy Ratings
Companies Covered
14 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy69.4%25 ratings
Hold25.0%9 ratings
Sell5.6%2 ratings

Out of 36 total stock ratings issued by Sean Laaman at Morgan Stanley, the majority (69.4%) have been Buy recommendations, followed by 25.0% Hold and 5.6% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.9% of companies on NASDAQ
13 companies
NYSE
7.1% of companies on NYSE
1 company

Sean Laaman, an analyst at Morgan Stanley, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
11 companies
78.6%
Manufacturing
3 companies
21.4%

Sean Laaman of Morgan Stanley specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
8 companies
57.1%
Miscellaneous
2 companies
14.3%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
7.1%
MED - GENERIC DRG
1 company
7.1%
MED - DRUGS
1 company
7.1%
MED PRODUCTS
1 company
7.1%

Sean Laaman's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Generate Biomedicines Inc stock logo
GENB
Generate Biomedicines
5/14/2026Boost Price Target$15.88$22.00Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
5/14/2026Boost Price Target$69.30$80.00Overweight
Certara, Inc. stock logo
CERT
Certara
5/12/2026Lower Price Target$5.13$10.00Equal Weight
Exelixis, Inc. stock logo
EXEL
Exelixis
5/6/2026Boost Price Target$48.45$50.00Equal Weight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
5/5/2026Boost Price Target$227.99$242.00Equal Weight
Generate Biomedicines Inc stock logo
GENB
Generate Biomedicines
3/24/2026Initiated Coverage$12.52$20.00Overweight
EIKN
EIKN
3/2/2026Initiated Coverage$13.78$32.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2/25/2026Boost Price Target$66.71$98.00Overweight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2/24/2026Set Price Target$170.97$207.00
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2/17/2026Set Price Target$60.55$75.00
Exelixis, Inc. stock logo
EXEL
Exelixis
2/2/2026Boost Price Target$41.23$49.00Equal Weight
Erasca, Inc. stock logo
ERAS
Erasca
1/26/2026Set Price Target$9.96$10.00
CG Oncology, Inc. stock logo
CGON
CG Oncology
1/9/2026Set Price Target$54.23$93.00
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
1/8/2026Reiterated Rating$333.87$405.00Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
1/8/2026Reiterated Rating$80.94$120.00Overweight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1/8/2026Downgrade$170.69Reduce
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1/8/2026Reiterated Rating$170.69$204.00Equal Weight
Exelixis, Inc. stock logo
EXEL
Exelixis
1/8/2026Reiterated Rating$46.19$48.00Equal Weight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
1/6/2026Initiated Coverage$73.42$96.00Overweight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
12/31/2025Reiterated Rating$183.22Overweight
Certara, Inc. stock logo
CERT
Certara
12/18/2025Lower Price Target$9.10$12.00Equal Weight
Maplight Therapeutics, Inc. stock logo
MPLT
Maplight Therapeutics
11/21/2025Initiated Coverage$13.29$34.00Overweight
Exelixis, Inc. stock logo
EXEL
Exelixis
11/5/2025Boost Price Target$40.36$45.00Overweight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
11/4/2025Boost Price Target$133.96$196.00Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
10/30/2025Boost Price Target$85.75$115.00Overweight
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
10/27/2025Boost Price Target$31.98$34.00Overweight
Exelixis, Inc. stock logo
EXEL
Exelixis
10/21/2025Lower Price Target$35.32$44.00Overweight
ResMed Inc. stock logo
RMD
ResMed
10/21/2025Boost Price Target$271.44$304.00Overweight
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
10/20/2025Boost Price Target$318.05$383.00Overweight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
10/20/2025Boost Price Target$127.94$194.00Overweight
Exelixis, Inc. stock logo
EXEL
Exelixis
9/17/2025Boost Price Target$40.54$50.00Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
8/18/2025Boost Price Target$60.07$90.00Overweight
Exelixis, Inc. stock logo
EXEL
Exelixis
7/29/2025Lower Price Target$37.20$46.00Overweight
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
7/3/2025Initiated Coverage$53.17$85.00Overweight
Certara, Inc. stock logo
CERT
Certara
7/3/2025Initiated Coverage$11.49$16.00Equal Weight
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
7/3/2025Initiated Coverage$103.91$190.00Overweight
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6/27/2025Boost Price Target$244.34$330.00Overweight
Alector, Inc. stock logo
ALEC
Alector
3/7/2025Reiterated Rating$1.48$1.50Underweight